MRNA is trading at $51.30 (+2.99%) amid ongoing gains after strong five-year Phase 2b data showed its personalized mRNA cancer therapy combined with Keytruda reduced death risk for high-risk melanoma patients by 49%.
- The stock hit a 52-week high yesterday following the initial release of the Moderna-Merck news.
- Today's move is aligning with broader market gains (S&P 500 +0.59%, Nasdaq +0.94%).
- Trading is occurring on elevated volume.